[ { "pmid": "40379536", "doi": "10.1016/j.bja.2025.04.001", "pmc": "PMC12597468", "title": "Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement", "authors": [ "Oprea AD", "Ostapenko LJ", "Sweitzer B", "Selzer A", "Irizarry-Alvarado JM", "Hurtado Andrade MD", "Mendez CE", "Kelley KD", "Stewart E", "Fernandez Robles CR", "Chadha RM", "Camilleri M", "Mathur R", "Umpierrez GE", "Hepner DL" ], "journal": "British journal of anaesthesia", "year": 2025, "type": "Systematic review", "evidence": 5, "topics": [ "glp1-mechanism" ] }, { "pmid": "39863261", "doi": "10.1053/j.ajkd.2024.11.013", "pmc": null, "title": "Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials", "authors": [ "Chen JY", "Hsu TW", "Liu JH", "Pan HC", "Lai CF", "Yang SY", "Wu VC" ], "journal": "American journal of kidney diseases : the official journal of the National Kidney Foundation", "year": 2025, "type": "Meta-analysis", "evidence": 5, "topics": [ "cardiovascular", "glp1-other" ] }, { "pmid": "39396098", "doi": "10.1038/s41366-024-01646-9", "pmc": null, "title": "Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis", "authors": [ "Cleto AS", "Schirlo JM", "Beltrame M", "Gomes VHO", "Acras IH", "Neiverth GS", "Silva BB", "Juliatto BMS", "Machozeki J", "Martins CM" ], "journal": "International journal of obesity (2005)", "year": 2025, "type": "Meta-analysis", "evidence": 5, "topics": [ "cardiovascular" ] }, { "pmid": "39719170", "doi": "10.1016/j.metabol.2024.156113", "pmc": null, "title": "Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis", "authors": [ "Karakasis P", "Patoulias D", "Fragakis N", "Mantzoros CS" ], "journal": "Metabolism: clinical and experimental", "year": 2025, "type": "Meta-analysis", "evidence": 5, "topics": [ "muscle-loss" ] }, { "pmid": "39952695", "doi": "10.1124/pharmrev.123.001045", "pmc": null, "title": "Emerging pharmacotherapies for obesity: A systematic review", "authors": [ "Kokkorakis M", "Chakhtoura M", "Rhayem C", "Al Rifai J", "Ghezzawi M", "Valenzuela-Vallejo L", "Mantzoros CS" ], "journal": "Pharmacological reviews", "year": 2025, "type": "Systematic review", "evidence": 5, "topics": [ "oral-glp1" ] }, { "pmid": "39608381", "doi": "10.1016/S2213-8587(24)00271-7", "pmc": null, "title": "Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials", "authors": [ "Badve SV", "Bilal A", "Lee MMY", "Sattar N", "Gerstein HC", "Ruff CT", "McMurray JJV", "Rossing P", "Bakris G", "Mahaffey KW", "Mann JFE", "Colhoun HM", "Tuttle KR", "Pratley RE", "Perkovic V" ], "journal": "The lancet. Diabetes & endocrinology", "year": 2025, "type": "Meta-analysis", "evidence": 5, "topics": [ "glp1-other" ] }, { "pmid": "38851997", "doi": "10.1016/j.jhep.2024.04.031", "pmc": null, "title": "EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)", "authors": [], "journal": "Journal of hepatology", "year": 2024, "type": "Clinical guideline", "evidence": 5, "topics": [ "semaglutide-weight", "tirzepatide" ] }, { "pmid": "38286487", "doi": "10.1136/bmj-2023-076410", "pmc": "PMC10823535", "title": "Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis", "authors": [ "Yao H", "Zhang A", "Li D", "Wu Y", "Wang CZ", "Wan JY", "Yuan CS" ], "journal": "BMJ (Clinical research ed.)", "year": 2024, "type": "Meta-analysis", "evidence": 5, "topics": [ "semaglutide-weight", "tirzepatide" ] }, { "pmid": "38679221", "doi": "10.1016/j.amjcard.2024.04.041", "pmc": null, "title": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "authors": [ "Moiz A", "Levett JY", "Filion KB", "Peri K", "Reynier P", "Eisenberg MJ" ], "journal": "The American journal of cardiology", "year": 2024, "type": "Meta-analysis", "evidence": 5, "topics": [ "semaglutide-weight" ] }, { "pmid": "38613667", "doi": "10.1007/s00125-024-06144-1", "pmc": "PMC11153294", "title": "Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials", "authors": [ "Karagiannis T", "Malandris K", "Avgerinos I", "Stamati A", "Kakotrichi P", "Liakos A", "Vasilakou D", "Kakaletsis N", "Tsapas A", "Bekiari E" ], "journal": "Diabetologia", "year": 2024, "type": "Meta-analysis", "evidence": 5, "topics": [ "tirzepatide" ] }, { "pmid": "38634551", "doi": "10.14309/ajg.0000000000002820", "pmc": "PMC11150091", "title": "Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management", "authors": [ "Hiramoto B", "McCarty TR", "Lodhia NA", "Jenkins A", "Elnaiem A", "Muftah M", "Flanagan R", "Chan WW" ], "journal": "The American journal of gastroenterology", "year": 2024, "type": "Meta-analysis", "evidence": 5, "topics": [ "glp1-mechanism" ] }, { "pmid": "38991584", "doi": "10.1016/S2213-8587(24)00155-4", "pmc": null, "title": "Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials", "authors": [ "Apperloo EM", "Neuen BL", "Fletcher RA", "Jongs N", "Anker SD", "Bhatt DL", "Butler J", "Cherney DZI", "Herrington WG", "Inzucchi SE", "Jardine MJ", "Liu CC", "Mahaffey KW", "McGuire DK", "McMurray JJV", "Neal B", "Packer M", "Perkovic V", "Sabatine MS", "Solomon SD", "Staplin N", "Szarek M", "Vaduganathan M", "Wanner C", "Wheeler DC", "Wiviott SD", "Zannad F", "Heerspink HJL" ], "journal": "The lancet. Diabetes & endocrinology", "year": 2024, "type": "Meta-analysis", "evidence": 5, "topics": [ "cardiovascular", "glp1-other" ] }, { "pmid": "38629387", "doi": "10.1080/14656566.2024.2343092", "pmc": null, "title": "A systematic review of the effect of semaglutide on lean mass: insights from clinical trials", "authors": [ "Bikou A", "Dermiki-Gkana F", "Penteris M", "Constantinides TK", "Kontogiorgis C" ], "journal": "Expert opinion on pharmacotherapy", "year": 2024, "type": "Systematic review", "evidence": 5, "topics": [ "muscle-loss" ] }, { "pmid": "37141329", "doi": "10.1371/journal.pone.0285197", "pmc": "PMC10159347", "title": "Weight loss efficiency and safety of tirzepatide: A Systematic review", "authors": [ "Lin F", "Yu B", "Ling B", "Lv G", "Shang H", "Zhao X", "Jie X", "Chen J", "Li Y" ], "journal": "PloS one", "year": 2023, "type": "Meta-analysis", "evidence": 5, "topics": [ "glp1-mechanism" ] }, { "pmid": "37024129", "doi": "10.1136/bmj-2022-074068", "pmc": "PMC10077111", "title": "Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials", "authors": [ "Shi Q", "Nong K", "Vandvik PO", "Guyatt GH", "Schnell O", "Rydén L", "Marx N", "Brosius FC 3rd", "Mustafa RA", "Agarwal A", "Zou X", "Mao Y", "Asadollahifar A", "Chowdhury SR", "Zhai C", "Gupta S", "Gao Y", "Lima JP", "Numata K", "Qiao Z", "Fan Q", "Yang Q", "Jin Y", "Ge L", "Yang Q", "Zhu H", "Yang F", "Chen Z", "Lu X", "He S", "Chen X", "Lyu X", "An X", "Chen Y", "Hao Q", "Standl E", "Siemieniuk R", "Agoritsas T", "Tian H", "Li S" ], "journal": "BMJ (Clinical research ed.)", "year": 2023, "type": "Meta-analysis", "evidence": 5, "topics": [ "glp1-other" ] }, { "pmid": "36578889", "doi": "10.15605/jafes.037.02.14", "pmc": "PMC9758543", "title": "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis", "authors": [ "Tan HC", "Dampil OA", "Marquez MM" ], "journal": "Journal of the ASEAN Federation of Endocrine Societies", "year": 2022, "type": "Meta-analysis", "evidence": 5, "topics": [ "semaglutide-weight" ] }, { "pmid": "35210595", "doi": "10.1038/s41591-022-01707-4", "pmc": "PMC8938269", "title": "Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis", "authors": [ "Sattar N", "McGuire DK", "Pavo I", "Weerakkody GJ", "Nishiyama H", "Wiese RJ", "Zoungas S" ], "journal": "Nature medicine", "year": 2022, "type": "Meta-analysis", "evidence": 5, "topics": [ "cardiovascular" ] }, { "pmid": "31422062", "doi": "10.1016/S2213-8587(19)30249-9", "pmc": null, "title": "Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials", "authors": [ "Kristensen SL", "Rørth R", "Jhund PS", "Docherty KF", "Sattar N", "Preiss D", "Køber L", "Petrie MC", "McMurray JJV" ], "journal": "The lancet. Diabetes & endocrinology", "year": 2019, "type": "Meta-analysis", "evidence": 5, "topics": [ "cardiovascular", "adverse-effects", "glp1-other" ] }, { "pmid": "29221659", "doi": "10.1016/S2213-8587(17)30412-6", "pmc": null, "title": "Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis", "authors": [ "Bethel MA", "Patel RA", "Merrill P", "Lokhnygina Y", "Buse JB", "Mentz RJ", "Pagidipati NJ", "Chan JC", "Gustavson SM", "Iqbal N", "Maggioni AP", "Öhman P", "Poulter NR", "Ramachandran A", "Zinman B", "Hernandez AF", "Holman RR" ], "journal": "The lancet. Diabetes & endocrinology", "year": 2018, "type": "Meta-analysis", "evidence": 5, "topics": [ "cardiovascular" ] }, { "pmid": "39536238", "doi": "10.1056/NEJMoa2410819", "pmc": null, "title": "Tirzepatide for Obesity Treatment and Diabetes Prevention", "authors": [ "Jastreboff AM", "le Roux CW", "Stefanski A", "Aronne LJ", "Halpern B", "Wharton S", "Wilding JPH", "Perreault L", "Zhang S", "Battula R", "Bunck MC", "Ahmad NN", "Jouravskaya I" ], "journal": "The New England journal of medicine", "year": 2025, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "tirzepatide" ] }, { "pmid": "39555826", "doi": "10.1056/NEJMoa2410027", "pmc": null, "title": "Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity", "authors": [ "Packer M", "Zile MR", "Kramer CM", "Baum SJ", "Litwin SE", "Menon V", "Ge J", "Weerakkody GJ", "Ou Y", "Bunck MC", "Hurt KC", "Murakami M", "Borlaug BA" ], "journal": "The New England journal of medicine", "year": 2025, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "tirzepatide" ] }, { "pmid": "40960239", "doi": "10.1056/NEJMoa2511774", "pmc": null, "title": "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment", "authors": [ "Wharton S", "Aronne LJ", "Stefanski A", "Alfaris NF", "Ciudin A", "Yokote K", "Halpern B", "Shukla AP", "Zhou C", "Macpherson L", "Allen SE", "Ahmad NN", "Klise SR" ], "journal": "The New England journal of medicine", "year": 2025, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "adverse-effects", "discontinuation", "oral-glp1" ] }, { "pmid": "40544435", "doi": "10.1056/NEJMoa2505669", "pmc": null, "title": "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes", "authors": [ "Rosenstock J", "Hsia S", "Nevarez Ruiz L", "Eyde S", "Cox D", "Wu WS", "Liu R", "Li J", "Fernández Landó L", "Denning M", "Ludwig L", "Chen Y" ], "journal": "The New England journal of medicine", "year": 2025, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "adverse-effects" ] }, { "pmid": "39996356", "doi": "10.1111/dom.16275", "pmc": "PMC11965027", "title": "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight", "authors": [ "Look M", "Dunn JP", "Kushner RF", "Cao D", "Harris C", "Gibble TH", "Stefanski A", "Griffin R" ], "journal": "Diabetes, obesity & metabolism", "year": 2025, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "muscle-loss" ] }, { "pmid": "40934115", "doi": "10.1056/NEJMoa2500969", "pmc": null, "title": "Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity", "authors": [ "Wharton S", "Lingvay I", "Bogdanski P", "Duque do Vale R", "Jacob S", "Karlsson T", "Shaji C", "Rubino D", "Garvey WT" ], "journal": "The New England journal of medicine", "year": 2025, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "oral-glp1" ] }, { "pmid": "38912654", "doi": "10.1056/NEJMoa2404881", "pmc": "PMC11598664", "title": "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity", "authors": [ "Malhotra A", "Grunstein RR", "Fietze I", "Weaver TE", "Redline S", "Azarbarzin A", "Sands SA", "Schwab RJ", "Dunn JP", "Chakladar S", "Bunck MC", "Bednarik J" ], "journal": "The New England journal of medicine", "year": 2024, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "tirzepatide" ] }, { "pmid": "39181597", "doi": "10.1016/S0140-6736(24)01498-3", "pmc": null, "title": "Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial", "authors": [ "Deanfield J", "Verma S", "Scirica BM", "Kahn SE", "Emerson SS", "Ryan D", "Lingvay I", "Colhoun HM", "Plutzky J", "Kosiborod MN", "Hovingh GK", "Hardt-Lindberg S", "Frenkel O", "Weeke PE", "Rasmussen S", "Goudev A", "Lang CC", "Urina-Triana M", "Pietilä M", "Lincoff AM" ], "journal": "Lancet (London, England)", "year": 2024, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "cardiovascular" ] }, { "pmid": "39476339", "doi": "10.1056/NEJMoa2403664", "pmc": null, "title": "Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis", "authors": [ "Bliddal H", "Bays H", "Czernichow S", "Uddén Hemmingsson J", "Hjelmesæth J", "Hoffmann Morville T", "Koroleva A", "Skov Neergaard J", "Vélez Sánchez P", "Wharton S", "Wizert A", "Kristensen LE" ], "journal": "The New England journal of medicine", "year": 2024, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "discontinuation" ] }, { "pmid": "38740993", "doi": "10.1038/s41591-024-02996-7", "pmc": "PMC11271387", "title": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "authors": [ "Ryan DH", "Lingvay I", "Deanfield J", "Kahn SE", "Barros E", "Burguera B", "Colhoun HM", "Cercato C", "Dicker D", "Horn DB", "Hovingh GK", "Jeppesen OK", "Kokkinos A", "Lincoff AM", "Meyhöfer SM", "Oral TK", "Plutzky J", "van Beek AP", "Wilding JPH", "Kushner RF" ], "journal": "Nature medicine", "year": 2024, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "oral-glp1" ] }, { "pmid": "37952131", "doi": "10.1056/NEJMoa2307563", "pmc": null, "title": "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes", "authors": [ "Lincoff AM", "Brown-Frandsen K", "Colhoun HM", "Deanfield J", "Emerson SS", "Esbjerg S", "Hardt-Lindberg S", "Hovingh GK", "Kahn SE", "Kushner RF", "Lingvay I", "Oral TK", "Michelsen MM", "Plutzky J", "Tornøe CW", "Ryan DH" ], "journal": "The New England journal of medicine", "year": 2023, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "semaglutide-weight", "discontinuation", "oral-glp1" ] }, { "pmid": "37385275", "doi": "10.1016/S0140-6736(23)01200-X", "pmc": null, "title": "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial", "authors": [ "Garvey WT", "Frias JP", "Jastreboff AM", "le Roux CW", "Sattar N", "Aizenberg D", "Mao H", "Zhang S", "Ahmad NN", "Bunck MC", "Benabbad I", "Zhang XM" ], "journal": "Lancet (London, England)", "year": 2023, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "tirzepatide" ] }, { "pmid": "37188932", "doi": "10.1111/dom.15113", "pmc": "PMC10544709", "title": "Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes", "authors": [ "Silver HJ", "Olson D", "Mayfield D", "Wright P", "Nian H", "Mashayekhi M", "Koethe JR", "Niswender KD", "Luther JM", "Brown NJ" ], "journal": "Diabetes, obesity & metabolism", "year": 2023, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "glp1-mechanism" ] }, { "pmid": "37364710", "doi": "10.1016/j.molmet.2023.101762", "pmc": "PMC10339203", "title": "Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog", "authors": [ "Guo W", "Xu Z", "Zou H", "Li F", "Li Y", "Feng J", "Zhu Z", "Zheng Q", "Zhu R", "Wang B", "Li Y", "Hao S", "Qin H", "Jones CL", "Adegbite E", "Telusca L", "Fenaux M", "Zhong W", "Junaidi MK", "Xu S", "Pan H" ], "journal": "Molecular metabolism", "year": 2023, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "glp1-mechanism" ] }, { "pmid": "37351564", "doi": "10.1056/NEJMoa2302392", "pmc": null, "title": "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity", "authors": [ "Wharton S", "Blevins T", "Connery L", "Rosenstock J", "Raha S", "Liu R", "Ma X", "Mather KJ", "Haupt A", "Robins D", "Pratt E", "Kazda C", "Konig M" ], "journal": "The New England journal of medicine", "year": 2023, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "adverse-effects" ] }, { "pmid": "36857477", "doi": "10.2337/dc22-1710", "pmc": "PMC10154650", "title": "Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes", "authors": [ "Heise T", "DeVries JH", "Urva S", "Li J", "Pratt EJ", "Thomas MK", "Mather KJ", "Karanikas CA", "Dunn J", "Haupt A", "Milicevic Z", "Coskun T" ], "journal": "Diabetes care", "year": 2023, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "muscle-loss" ] }, { "pmid": "37385278", "doi": "10.1016/S0140-6736(23)01185-6", "pmc": null, "title": "Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial", "authors": [ "Knop FK", "Aroda VR", "do Vale RD", "Holst-Hansen T", "Laursen PN", "Rosenstock J", "Rubino DM", "Garvey WT" ], "journal": "Lancet (London, England)", "year": 2023, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "oral-glp1" ] }, { "pmid": "35441470", "doi": "10.1111/dom.14725", "pmc": "PMC9542252", "title": "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension", "authors": [ "Wilding JPH", "Batterham RL", "Davies M", "Van Gaal LF", "Kandler K", "Konakli K", "Lingvay I", "McGowan BM", "Oral TK", "Rosenstock J", "Wadden TA", "Wharton S", "Yokote K", "Kushner RF" ], "journal": "Diabetes, obesity & metabolism", "year": 2022, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "semaglutide-weight", "discontinuation", "oral-glp1" ] }, { "pmid": "35658024", "doi": "10.1056/NEJMoa2206038", "pmc": null, "title": "Tirzepatide Once Weekly for the Treatment of Obesity", "authors": [ "Jastreboff AM", "Aronne LJ", "Ahmad NN", "Wharton S", "Connery L", "Alves B", "Kiyosue A", "Zhang S", "Liu B", "Bunck MC", "Stefanski A" ], "journal": "The New England journal of medicine", "year": 2022, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "tirzepatide" ] }, { "pmid": "35131037", "doi": "10.1016/S2213-8587(22)00008-0", "pmc": null, "title": "Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial", "authors": [ "Kadowaki T", "Isendahl J", "Khalid U", "Lee SY", "Nishida T", "Ogawa W", "Tobe K", "Yamauchi T", "Lim S" ], "journal": "The lancet. Diabetes & endocrinology", "year": 2022, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "muscle-loss" ] }, { "pmid": "36216945", "doi": "10.1038/s41591-022-02026-4", "pmc": "PMC9556320", "title": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "authors": [ "Garvey WT", "Batterham RL", "Bhatta M", "Buscemi S", "Christensen LN", "Frias JP", "Jódar E", "Kandler K", "Rigas G", "Wadden TA", "Wharton S" ], "journal": "Nature medicine", "year": 2022, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "discontinuation" ] }, { "pmid": "35468325", "doi": "10.1016/S2213-8587(22)00070-5", "pmc": null, "title": "Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial", "authors": [ "Gastaldelli A", "Cusi K", "Fernández Landó L", "Bray R", "Brouwers B", "Rodríguez Á" ], "journal": "The lancet. Diabetes & endocrinology", "year": 2022, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "glp1-other" ] }, { "pmid": "36066977", "doi": "10.1172/jci.insight.159863", "pmc": "PMC9675448", "title": "Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial", "authors": [ "Klausen MK", "Jensen ME", "Møller M", "Le Dous N", "Jensen AØ", "Zeeman VA", "Johannsen CF", "Lee A", "Thomsen GK", "Macoveanu J", "Fisher PM", "Gillum MP", "Jørgensen NR", "Bergmann ML", "Enghusen Poulsen H", "Becker U", "Holst JJ", "Benveniste H", "Volkow ND", "Vollstädt-Klein S", "Miskowiak KW", "Ekstrøm CT", "Knudsen GM", "Vilsbøll T", "Fink-Jensen A" ], "journal": "JCI insight", "year": 2022, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "glp1-other" ] }, { "pmid": "36152639", "doi": "10.1016/S2213-8587(22)00243-1", "pmc": null, "title": "Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial", "authors": [ "Heerspink HJL", "Sattar N", "Pavo I", "Haupt A", "Duffin KL", "Yang Z", "Wiese RJ", "Tuttle KR", "Cherney DZI" ], "journal": "The lancet. Diabetes & endocrinology", "year": 2022, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "glp1-other" ] }, { "pmid": "33567185", "doi": "10.1056/NEJMoa2032183", "pmc": null, "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity", "authors": [ "Wilding JPH", "Batterham RL", "Calanna S", "Davies M", "Van Gaal LF", "Lingvay I", "McGowan BM", "Rosenstock J", "Tran MTD", "Wadden TA", "Wharton S", "Yokote K", "Zeuthen N", "Kushner RF" ], "journal": "The New England journal of medicine", "year": 2021, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "semaglutide-weight", "muscle-loss", "discontinuation" ] }, { "pmid": "33755728", "doi": "10.1001/jama.2021.3224", "pmc": "PMC7988425", "title": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial", "authors": [ "Rubino D", "Abrahamsson N", "Davies M", "Hesse D", "Greenway FL", "Jensen C", "Lingvay I", "Mosenzon O", "Rosenstock J", "Rubio MA", "Rudofsky G", "Tadayon S", "Wadden TA", "Dicker D" ], "journal": "JAMA", "year": 2021, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "semaglutide-weight", "discontinuation" ] }, { "pmid": "33667417", "doi": "10.1016/S0140-6736(21)00213-0", "pmc": null, "title": "Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial", "authors": [ "Davies M", "Færch L", "Jeppesen OK", "Pakseresht A", "Pedersen SD", "Perreault L", "Rosenstock J", "Shimomura I", "Viljoen A", "Wadden TA", "Lingvay I" ], "journal": "Lancet (London, England)", "year": 2021, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "semaglutide-weight" ] }, { "pmid": "34170647", "doi": "10.1056/NEJMoa2107519", "pmc": null, "title": "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes", "authors": [ "Frías JP", "Davies MJ", "Rosenstock J", "Pérez Manghi FC", "Fernández Landó L", "Bergman BK", "Liu B", "Cui X", "Brown K" ], "journal": "The New England journal of medicine", "year": 2021, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "tirzepatide", "adverse-effects" ] }, { "pmid": "33269530", "doi": "10.1111/dom.14280", "pmc": "PMC7898914", "title": "The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity", "authors": [ "Friedrichsen M", "Breitschaft A", "Tadayon S", "Wizert A", "Skovgaard D" ], "journal": "Diabetes, obesity & metabolism", "year": 2021, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "glp1-mechanism" ] }, { "pmid": "34186022", "doi": "10.1016/S0140-6736(21)01324-6", "pmc": null, "title": "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial", "authors": [ "Rosenstock J", "Wysham C", "Frías JP", "Kaneko S", "Lee CJ", "Fernández Landó L", "Mao H", "Cui X", "Karanikas CA", "Thieu VT" ], "journal": "Lancet (London, England)", "year": 2021, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "adverse-effects" ] }, { "pmid": "31189511", "doi": "10.1016/S0140-6736(19)31149-3", "pmc": null, "title": "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial", "authors": [ "Gerstein HC", "Colhoun HM", "Dagenais GR", "Diaz R", "Lakshmanan M", "Pais P", "Probstfield J", "Riesmeyer JS", "Riddle MC", "Rydén L", "Xavier D", "Atisso CM", "Dyal L", "Hall S", "Rao-Melacini P", "Wong G", "Avezum A", "Basile J", "Chung N", "Conget I", "Cushman WC", "Franek E", "Hancu N", "Hanefeld M", "Holt S", "Jansky P", "Keltai M", "Lanas F", "Leiter LA", "Lopez-Jaramillo P", "Cardona Munoz EG", "Pirags V", "Pogosova N", "Raubenheimer PJ", "Shaw JE", "Sheu WH", "Temelkova-Kurktschiev T" ], "journal": "Lancet (London, England)", "year": 2019, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "cardiovascular", "adverse-effects" ] }, { "pmid": "30473097", "doi": "10.1016/j.molmet.2018.09.009", "pmc": "PMC6308032", "title": "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept", "authors": [ "Coskun T", "Sloop KW", "Loghin C", "Alsina-Fernandez J", "Urva S", "Bokvist KB", "Cui X", "Briere DA", "Cabrera O", "Roell WC", "Kuchibhotla U", "Moyers JS", "Benson CT", "Gimeno RE", "D'Alessio DA", "Haupt A" ], "journal": "Molecular metabolism", "year": 2018, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "glp1-mechanism", "adverse-effects" ] }, { "pmid": "28266779", "doi": "10.1111/dom.12932", "pmc": "PMC5573908", "title": "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity", "authors": [ "Blundell J", "Finlayson G", "Axelsen M", "Flint A", "Gibbons C", "Kvist T", "Hjerpsted JB" ], "journal": "Diabetes, obesity & metabolism", "year": 2017, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "glp1-mechanism", "muscle-loss" ] }, { "pmid": "27633186", "doi": "10.1056/NEJMoa1607141", "pmc": null, "title": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes", "authors": [ "Marso SP", "Bain SC", "Consoli A", "Eliaschewitz FG", "Jódar E", "Leiter LA", "Lingvay I", "Rosenstock J", "Seufert J", "Warren ML", "Woo V", "Hansen O", "Holst AG", "Pettersson J", "Vilsbøll T" ], "journal": "The New England journal of medicine", "year": 2016, "type": "Randomised controlled trial", "evidence": 4, "topics": [ "discontinuation" ] }, { "pmid": "41931049", "doi": "10.1056/NEJMra2500106", "pmc": null, "title": "GLP-1 Receptor Agonists", "authors": [ "Rosen CJ", "Ingelfinger JR" ], "journal": "The New England journal of medicine", "year": 2026, "type": "Review", "evidence": 3, "topics": [ "glp1-mechanism" ] }, { "pmid": "41201884", "doi": "10.1097/HEP.0000000000001608", "pmc": null, "title": "Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance", "authors": [ "Bansal MB", "Patton H", "Morgan TR", "Carr RM", "Dranoff JA", "Allen AM" ], "journal": "Hepatology (Baltimore, Md.)", "year": 2026, "type": "Review", "evidence": 3, "topics": [ "muscle-loss" ] }, { "pmid": "40353578", "doi": "10.1056/NEJMoa2416394", "pmc": null, "title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity", "authors": [ "Aronne LJ", "Horn DB", "le Roux CW", "Ho W", "Falcon BL", "Gomez Valderas E", "Das S", "Lee CJ", "Glass LC", "Senyucel C", "Dunn JP" ], "journal": "The New England journal of medicine", "year": 2025, "type": "Clinical trial", "evidence": 3, "topics": [ "semaglutide-weight", "tirzepatide" ] }, { "pmid": "41406444", "doi": "10.1056/NEJMoa2505928", "pmc": null, "title": "Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes", "authors": [ "Nicholls SJ", "Pavo I", "Bhatt DL", "Buse JB", "Del Prato S", "Kahn SE", "Lincoff AM", "McGuire DK", "Miller D", "Nauck MA", "Nishiyama H", "Nissen SE", "Sattar N", "Weerakkody G", "Wiese RJ", "Zinman B", "Zoungas S", "Basile J", "Davies MJ", "Giorgino F", "Kellerer M", "Ji L", "Varkonyi T", "Menon V", "Broder JC", "Herschtal A", "D'Alessio D" ], "journal": "The New England journal of medicine", "year": 2025, "type": "Clinical trial", "evidence": 3, "topics": [ "tirzepatide" ] }, { "pmid": "39892489", "doi": "10.1016/j.amjmed.2025.01.021", "pmc": null, "title": "Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation", "authors": [ "Moiz A", "Filion KB", "Tsoukas MA", "Yu OH", "Peters TM", "Eisenberg MJ" ], "journal": "The American journal of medicine", "year": 2025, "type": "Review", "evidence": 3, "topics": [ "glp1-mechanism" ] }, { "pmid": "40196933", "doi": "10.1111/dom.16364", "pmc": "PMC12000858", "title": "Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies", "authors": [ "Thomsen RW", "Mailhac A", "Løhde JB", "Pottegård A" ], "journal": "Diabetes, obesity & metabolism", "year": 2025, "type": "Review", "evidence": 3, "topics": [ "adverse-effects" ] }, { "pmid": "37758044", "doi": "10.1016/j.ahj.2023.09.007", "pmc": null, "title": "Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics", "authors": [ "Nicholls SJ", "Bhatt DL", "Buse JB", "Prato SD", "Kahn SE", "Lincoff AM", "McGuire DK", "Nauck MA", "Nissen SE", "Sattar N", "Zinman B", "Zoungas S", "Basile J", "Bartee A", "Miller D", "Nishiyama H", "Pavo I", "Weerakkody G", "Wiese RJ", "D'Alessio D" ], "journal": "American heart journal", "year": 2024, "type": "Clinical trial", "evidence": 3, "topics": [ "cardiovascular" ] }, { "pmid": "38015216", "doi": "10.1001/jama.2023.19897", "pmc": "PMC11325826", "title": "Obesity Management in Adults: A Review", "authors": [ "Elmaleh-Sachs A", "Schwartz JL", "Bramante CT", "Nicklas JM", "Gudzune KA", "Jay M" ], "journal": "JAMA", "year": 2023, "type": "Review", "evidence": 3, "topics": [ "discontinuation" ] }, { "pmid": "37271131", "doi": "10.1159/000531379", "pmc": null, "title": "Chronic Kidney Disease and Obesity", "authors": [ "Hojs R", "Ekart R", "Bevc S", "Vodošek Hojs N" ], "journal": "Nephron", "year": 2023, "type": "Review", "evidence": 3, "topics": [ "glp1-other" ] }, { "pmid": "38976257", "doi": "10.1001/jamainternmed.2024.2525", "pmc": "PMC11231910", "title": "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity", "authors": [ "Rodriguez PJ", "Goodwin Cartwright BM", "Gratzl S", "Brar R", "Baker C", "Gluckman TJ", "Stucky NL" ], "journal": "JAMA internal medicine", "year": 2024, "type": "Journal article", "evidence": 2, "topics": [ "semaglutide-weight", "tirzepatide" ] }, { "pmid": "38935778", "doi": "10.1126/science.adj2537", "pmc": "PMC11961025", "title": "GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans", "authors": [ "Kim KS", "Park JS", "Hwang E", "Park MJ", "Shin HY", "Lee YH", "Kim KM", "Gautron L", "Godschall E", "Portillo B", "Grose K", "Jung SH", "Baek SL", "Yun YH", "Lee D", "Kim E", "Ajwani J", "Yoo SH", "Güler AD", "Williams KW", "Choi HJ" ], "journal": "Science (New York, N.Y.)", "year": 2024, "type": "Journal article", "evidence": 2, "topics": [ "glp1-mechanism" ] }, { "pmid": "36751934", "doi": "10.4140/TCP.n.2023.50", "pmc": null, "title": "New Drug: Tirzepatide (Mounjaro(™))", "authors": [ "Gettman L" ], "journal": "The Senior care pharmacist", "year": 2023, "type": "Journal article", "evidence": 2, "topics": [ "cardiovascular" ] }, { "pmid": "34425083", "doi": "10.1016/S2213-8587(21)00203-5", "pmc": null, "title": "Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials", "authors": [ "Sattar N", "Lee MMY", "Kristensen SL", "Branch KRH", "Del Prato S", "Khurmi NS", "Lam CSP", "Lopes RD", "McMurray JJV", "Pratley RE", "Rosenstock J", "Gerstein HC" ], "journal": "The lancet. Diabetes & endocrinology", "year": 2021, "type": "Journal article", "evidence": 2, "topics": [ "glp1-other" ] } ]